Class Action

Welcome to Class Dismissed

Morrison & Foerster’s Class Dismissed blog provides insights and reports on the latest news, developments, and trends that affect consumer-facing companies. Subscribe to receive the latest updates by attorneys from our nationally recognized Consumer Class Action and Product Liability practices.
January 7, 2021 - Autonomous Vehicles & Robotics, CPSC, Class Action, Consumer Products, Coronavirus (COVID-19), Emergency Use Authorization (EUA), MDL, Product Liability, Public Readiness and Emergency Preparedness Act (PREP Act)

How 2020 Changed Product Liability — And What's Next

By: Erin M. Bosman, Julie Y. Park, Alexandra Preece Barlow, Erin P. Lupfer, Benjamin S. Kagel, and Alexander A. Najarian

Erin Bosman, Julie Park, and Alexandra Preece authored an article for Law360 discussing how product liability regulation and litigation changed in 2020 due to the impact of the COVID-19 pandemic, as well as upcoming trends. “In a year dominated by the pandemic and political gridlock …›

January 6, 2021 - Class Action, Privacy

Privacy Litigation 2020 Year in Review: CCPA Litigation

By: Mark David McPherson, Purvi G. Patel, and Michael Burshteyn

In part two of our Privacy Litigation Year in Review series, we discuss how plaintiffs are challenging the limits of the California Consumer Privacy Act’s (CCPA) private right of action. In every respect, plaintiffs are trying to expand the private right of action. Given …›

January 4, 2021 - Class Action, Privacy

Privacy Litigation 2020 Year in Review: Data Breach Litigation

By: Nancy R. Thomas, Zachary Maldonado, and Ani Oganesian

2020: the year that will be remembered for privacy litigation. Well, OK, maybe not. But there were many developments in privacy litigation. In this four-part series, we will cover the key litigation developments arising out of data breaches, the California Consumer Privacy Act, the …›

December 28, 2020 - Coronavirus (COVID-19), FDA, Product Liability

FDA’s COVID-19 Product Regulation Enforcement Roadmap

By: Erin M. Bosman, Bethany J. Hills, Julie Y. Park, and Alexander A. Najarian

Navigating FDA’s regulatory enforcement strategies is paramount to successfully marketing health and medical products for COVID‑19—especially since the pandemic has dominated FDA’s enforcement activity this year. Understanding the patterns and principles behind FDA’s efforts can provide the insight product manufacturers need to avoid FDA …›

November 24, 2020 - Announcements & Press, Class Action, Coronavirus (COVID-19), Drug & Medical Device, MDL, Product Liability, Public Readiness and Emergency Preparedness Act (PREP Act)

Join Us: Drug & Medical Device Litigation Conference

By: Erin M. Bosman and Julie Y. Park

MoFo is a proud sponsor of the American Conference Institute’s Drug & Medical Device Litigation Conference, the premier products liability litigation event for the pharmaceutical and medical device industries for the past 24 years, to be held virtually on December 8 – 9, 2020. Erin …›

November 5, 2020 - Class Action, MDL

A Rule 23 Negotiation Class? Not So Fast!

By: David J. Fioccola and Robert J. Baehr

In the sprawling National Prescription Opiate Litigation (MDL 2804), proponents of a “negotiation class” recently asked the Sixth Circuit for en banc review of a September 2020 decision that struck down the novel class mechanism. Arguing that the 2-1 panel decision imposed an impermissibly …›